The study included 70 patients (24.3% under 35yo), with a median age of 37 years old. Invasive ductal carcinoma was the predominant histology (97.1%) of which 55.7% had a grade 3 of differentiation. At a median follow up of 107 months (8-146); 4 (5.7%) patients locally relapsed; 6 (8.6%) died, 5 due to cancer progression, finally 15 (21.4%) patients progressed to metastatic disease. 8 patients were lost during the follow up. From the total of 70 patients, 16 (22,8%) were categorized as triple negative, 4 (25%) of them were younger than 35 years old, including 2 (50%) who developed local recurrence.
The overall survival for 5 and 10 years were 97,1% and 91,4% respectively. Local recurrence survival was 97,1% at 5 years and 94,3% at 10 years. Patient 35 years old or less had higher rate of recurrence compared with the 35 to 40 years old group (17.6% vs 1.9%; p=0.009); difference also seen for overall (88,2% vs 92,5%; p=0,5), disease specific (88,2% vs 94,3%; p=0,3) and metastasis free survival (82,4% vs 90,6%; p=0,3). Stratifying patients by hormone receptor status, we found a tendency, no statically significative, for worst outcomes in patients with the absence of receptors (triple negative); OS (93,8% vs 90,7%; p=0,7), LCS (87,5% vs 96,4%; p=0,2) and MFS (87,5% vs 88,9%; p=0,9). In terms of cosmetic outcomes, it was valuated in 57 patients. 54 (94,7%) had an excellent-good result and 3 patients (5,3%) were classified as bad.
